Choreo LLC Makes New $59,000 Investment in Savara Inc (NASDAQ:SVRA)

Choreo LLC purchased a new position in shares of Savara Inc (NASDAQ:SVRA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,658 shares of the company’s stock, valued at approximately $59,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. acquired a new stake in shares of Savara during the 2nd quarter valued at about $527,000. Principal Financial Group Inc. grew its position in shares of Savara by 64.4% during the 2nd quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock valued at $72,000 after acquiring an additional 6,973 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Savara by 967.6% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 44,008 shares of the company’s stock valued at $177,000 after acquiring an additional 39,886 shares during the period. Bank of New York Mellon Corp grew its position in shares of Savara by 12.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 288,325 shares of the company’s stock valued at $1,162,000 after acquiring an additional 32,142 shares during the period. Finally, Opaleye Management Inc. acquired a new stake in shares of Savara during the 1st quarter valued at about $4,258,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Stock Performance

NASDAQ SVRA opened at $4.49 on Friday. The company has a market cap of $620.47 million, a PE ratio of -12.14 and a beta of 0.97. The stock’s 50 day simple moving average is $4.38 and its 200-day simple moving average is $4.50. Savara Inc has a 1-year low of $3.12 and a 1-year high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, equities research analysts anticipate that Savara Inc will post -0.44 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SVRA. Oppenheimer raised their target price on Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Savara in a research report on Wednesday, August 14th. JMP Securities restated a “market outperform” rating and set a $9.00 target price on shares of Savara in a research report on Monday, September 9th. Finally, Guggenheim lifted their price objective on Savara from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $11.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.